Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roivant Sciences Ltd.

10.99
+0.02000.18%
Post-market: 10.90-0.0900-0.82%16:27 EDT
Volume:3.31M
Turnover:36.30M
Market Cap:7.47B
PE:-46.35
High:11.03
Open:11.01
Low:10.93
Close:10.97
Loading ...

BRIEF-Roivant Sciences Authorizes $500 Million Share Repurchase Program

Reuters
·
25 Jun

Roivant Sciences Ltd - Authorizes $500 Mln Share Repurchase Program - SEC Filing

THOMSON REUTERS
·
25 Jun

Eric Venker, President & COO, Reports Disposal of Roivant Sciences Ltd. Common Shares

Reuters
·
25 Jun

Vivek Ramaswamy, 10% Owner, Reports Disposal of Common Shares in Roivant Sciences Ltd

Reuters
·
23 Jun

Law Firm Launches Investigation into Immunovant Inc. Over Alleged Fiduciary Breaches in Private Placement Deal

Reuters
·
21 Jun

Cantor Fitzgerald Sticks to Their Buy Rating for Roivant Sciences (ROIV)

TIPRANKS
·
18 Jun

Roivant Sciences Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Jun

JPMorgan positive on Roivant into dermatomyositis readout

TIPRANKS
·
18 Jun

Vivek Ramaswamy, 10% Owner, Reports Disposal of Common Shares in Roivant Sciences Ltd

Reuters
·
07 Jun

Roivant Sciences Ltd. President & COO Eric Venker Reports Disposal of Common Shares

Reuters
·
05 Jun

Guggenheim Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

TIPRANKS
·
30 May

Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Immunovant (IMVT) and Roivant Sciences (ROIV)

TIPRANKS
·
30 May

Stock Track | Roivant Sciences Soars 5.13% on Better-Than-Expected Q4 Results and Clinical Trial Progress

Stock Track
·
29 May

Stock Track | Roivant Sciences Soars 5.13% on Better-Than-Expected Earnings and Clinical Trial Progress

Stock Track
·
29 May

Roivant Sciences Ltd reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
29 May

Earnings Flash (ROIV) Roivant Posts Fiscal Q4 Net Loss $0.29 a Share, vs. FactSet Est of $0.31 Loss

MT Newswires Live
·
29 May

Roivant Sciences Q4 2024 Adj. EPS $(0.22) Misses $(0.16) Estimate, Sales $7.57M May Not Be Comparable To $62.17M Estimate

Benzinga
·
29 May

BRIEF-Roivant Sciences Q4 Operating Expenses USD 292.535 Million

Reuters
·
29 May

Roivant Sciences Reports $729.8M Net Loss for Fiscal Year 2025, EPS Drops to $0.75 from $5.95 in 2024

Reuters
·
29 May

Roivant Sciences Q4 Operating Expenses USD 292.535 Million

THOMSON REUTERS
·
29 May